The Australian Peritoneal Dialysis Outcomes And Practice Patterns Study (PDOPPS)
Funder
National Health and Medical Research Council
Funding Amount
$489,749.00
Summary
Peritoneal dialysis (PD) is a form of home dialysis that is both substantially cheaper and associated with better early survival than standard hospital-based haemodialysis. Its use in Australia has been severely limited by poor outcomes compared to the rest of the world. This international study aims to identify “real world” PD centre practices that will lead to better outcomes for Australian patients, greater uptake of home dialysis and health savings of tens of millions of dollars annually.
Therapeutic Potential Of Peritoneal Mononuclear Phagocytes From Peritoneal Dialysis Patients
Funder
National Health and Medical Research Council
Funding Amount
$375,817.00
Summary
Mononuclear phagocytes (MP) are key cells which are now being used to treat various diseases. In Australia, more than 10 million end stage kidney disease(ESKD) patients are treated with chronic dialysis, and more than 20% of them are on peritoneal dialysis (PD). Each PD patient discards more than 20 million MP in dialysate daily. We will explore the possibility of using these MP to treat diseases including transplant rejection.
Macrophages: A Therapeutic Target In Peritoneal Dialysis-induced Fibrosis?
Funder
National Health and Medical Research Council
Funding Amount
$593,888.00
Summary
Fibrosis (scar tissue) in the abdominal cavity is a common side-effect of peritoneal dialysis (a treatment for kidney failure), and results in a life-threatening loss of dialysis function. The cells causing the fibrosis are uncertain. This project asks: Are inflammatory cells (macrophages) the source of peritoneal scar tissue? What regulates the fibrotic process? Answers may lead to strategies to prevent fibrosis induced by peritoneal dialysis, abdominal surgery or other causes.